Therapeutic Solutions International Announces the
Post# of 18391
(Total Views: 127)
Posted On: 07/24/2018 10:55:01 AM
Therapeutic Solutions International Announces the Appointment of James Veltmeyer, MD as Chief Medical Officer
Published 9:00 AM ET Mon, 18 June 2018
Globe Newswire
OCEANSIDE, Calif., June 18, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Therapeutics Solutions International, Inc., (OTC Markets:TSOI) previously announced their plans to provide access to its clinical stage cancer immunotherapy product StemVacs under the Right To Try law signed by President Trump on May 30th 2018, and have appointed Dr. James Veltmeyer as Chief Medical Officer of their future planned cancer clinic.
"Having Dr. Veltmeyer head up our future "Right To Try Cancer Clinic", as well as all other clinical programs underway is a dream come true for TSOI," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "In his role as Chief of the Department of Family Medicine at Sharp Grossmont Hospital, where he currently provides senior leadership to over 200 physicians, Dr. Veltmeyer has developed skills that few ever do, allowing him to bring a wealth of experience in management and medicine to bear on our programs. He is one of the most compassionate doctors I have ever known and he will be an amazing Chief Medical Officer to oversee our future clinic where we plan to treat the most critically ill among us, end-stage cancer patients," added Mr. Dixon.
"The future of medicine is unfolding right before our eyes at a very rapid pace. Cellular immunotherapies, such as the Company's StemVacs platform allow for reprogramming of the immune system to selectively attack the cancer stem cell, which is believed to be the root of tumor formation," said Dr. James Veltmeyer. "Having worked with the team at TSOI since joining their Scientific Advisory Board, I have been impressed at the Company's pragmatic approach towards hyper-accelerated therapeutics development. I look forward to my more involved role in leading clinical translation of the Company's discoveries from Bench to Bedside."
"There are very few people I know who can transition seamlessly from business to medicine, to basic research," said Thomas Ichim, Ph.D., Director of TSOI. "I have worked closely with Dr. Veltmeyer both at TSOI, and as well on his Congressional Campaign. Dr. Veltmeyer is a naturally born leader that cares #1 about patients. I look forward to working alongside Dr. Veltmeyer in transforming the future of medicine," added Dr. Ichim.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or
Published 9:00 AM ET Mon, 18 June 2018
Globe Newswire
OCEANSIDE, Calif., June 18, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Therapeutics Solutions International, Inc., (OTC Markets:TSOI) previously announced their plans to provide access to its clinical stage cancer immunotherapy product StemVacs under the Right To Try law signed by President Trump on May 30th 2018, and have appointed Dr. James Veltmeyer as Chief Medical Officer of their future planned cancer clinic.
"Having Dr. Veltmeyer head up our future "Right To Try Cancer Clinic", as well as all other clinical programs underway is a dream come true for TSOI," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "In his role as Chief of the Department of Family Medicine at Sharp Grossmont Hospital, where he currently provides senior leadership to over 200 physicians, Dr. Veltmeyer has developed skills that few ever do, allowing him to bring a wealth of experience in management and medicine to bear on our programs. He is one of the most compassionate doctors I have ever known and he will be an amazing Chief Medical Officer to oversee our future clinic where we plan to treat the most critically ill among us, end-stage cancer patients," added Mr. Dixon.
"The future of medicine is unfolding right before our eyes at a very rapid pace. Cellular immunotherapies, such as the Company's StemVacs platform allow for reprogramming of the immune system to selectively attack the cancer stem cell, which is believed to be the root of tumor formation," said Dr. James Veltmeyer. "Having worked with the team at TSOI since joining their Scientific Advisory Board, I have been impressed at the Company's pragmatic approach towards hyper-accelerated therapeutics development. I look forward to my more involved role in leading clinical translation of the Company's discoveries from Bench to Bedside."
"There are very few people I know who can transition seamlessly from business to medicine, to basic research," said Thomas Ichim, Ph.D., Director of TSOI. "I have worked closely with Dr. Veltmeyer both at TSOI, and as well on his Congressional Campaign. Dr. Veltmeyer is a naturally born leader that cares #1 about patients. I look forward to working alongside Dr. Veltmeyer in transforming the future of medicine," added Dr. Ichim.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or
(0)
(0)